glp 1 mimetic Non-insulin injectable antidiabetic drugs - GLP-1 agonists and amylinomimetics Clinical Focus on GLP-1 Agonists
Description
Diabetes is a medical condition caused due to improper balance of glucose levels in the blood
As consumers continue to take their health and wellness goals seriously, GLP-1 drug usage will continue to grow.
Background In idiopathic intracranial hypertension (IIH), sustained weight loss is the main pillar in modifying disease course, whereby glucagon-like peptide-1 receptor agonists (GLP-1-RAs) could present an attractive treatment option
The Global GLP-1 Receptor Agonists Obesity Drugs Market was valued at USD 9.96 Billion in 2024 and is expected to reach USD 33.12 Billion by 2032, growing at a CAGR of 16.20% (2025-2032).
Explore how GLP-1 receptor agonists may help manage weight regain after bariatric surgery
